Multidrug Antifungal Resistance and Clinical Outcomes in Fungal Keratitis: A Prospective Study in a South Indian Population

Leonie Fingerhut[a]; Ramakrishnan Vigneshwar[b]; Florence Burté[a]; Manojkumar Vimala Devi[c]; Rathinavel Sethu Nagarajan[c]; Rajarathinam Karpagam[c]; Venkatesh Prajna[b]; Bethany Mills[a]* and Prajna Lalitha[c*]

[a] Institute for Regeneration and Repair, The University of Edinburgh, EH16 4UU, UK

[b] Department of Cornea, Aravind Eye Care System, Madurai, 625 020, India

[c] Department of Ocular Microbiology, Aravind Eye Care System, Madurai, 625 020, India

*Dr Bethany Mills and Dr Prajna Lalitha contributed equally as co-senior authors.

Correspondence to Dr Prajna Lalitha (lalitha@aravind.org) and Dr Bethany Mills (beth.mills@ed.ac.uk).

Key words:

Fungal keratitis; antifungal resistance; multidrug resistance; natamycin resistance; amphotericin B resistance; corneal infection.

Abstract:

Objectives: Our primary objective was to identify the rate of anti-fungal resistance (including multidrug resistance) of fungal isolates cultured from fungal keratitis patients in South India. Our secondary objective was to identify associations between antifungal resistance and patient outcome.

Subjects/Methods: 153 patients attending the cornea clinic at Aravind Eye Hospital, Madurai (May – August 2025) with culture positive fungal keratitis were enrolled in the study. Cultured isolates were evaluated for natamycin, amphotericin B, voriconazole and econazole MIC (n=151-153). MIC data were analysed by Kruskal-Wallis test followed by Dunn's multiple comparisons test. Patient disease outcome relative to isolate resistance was analysed by fisher's exact test (n=91).

Results: There were high levels of resistance to all four antifungals, which were significantly elevated in *Fusarium* spp. and *Aspergillus* spp. isolates compared to other fungal genera ($P<0.0001$). Resistance of *Fusarium* spp. isolates (n= 81) to: natamycin: 38.3%; amphotericin B: 93.8%; voriconazole: 97.5% and econazole: 76.5%. Resistance of *Aspergillus spp.* isolates (n=33) to: natamycin: 66.7%; amphotericin B: 87.9%; voriconazole: 6.1%; and econazole: 0%. Overall, fungal resistance to natamycin significantly correlated with a poor clinical outcome, P=0.0034, relative risk 1.7 (95% CI: 1.2-2.6).

Conclusions: The majority of fungal isolates were resistant to multiple antifungals; none of the *Fusarium* isolates were susceptible to all four drugs, 15% were resistant to all of them. Resistance towards natamycin may worsen clinical outcome, particularly for infections caused by *Aspergillus*, even when susceptible to azoles. Our data supports the need for species specific MIC thresholds to have increased clinical utility.

Introduction

Fungal keratitis remains a leading cause of visual impairment, blindness and eye-loss worldwide. It affects more than one million people annually, and corneal perforation is reported in up to 25% of cases (1, 2). While incidence is increasing across temperate climates, fungal keratitis disproportionately affects rural populations across the tropics, where the ophthalmic community has campaigned for neglected tropical disease status (3-7).

Fungal keratitis is challenging to treat, resulting in worse outcomes compared to bacterial keratitis (8, 9). Treatment relies on topical application of antifungal eye-drops, and options are limited, primarily to two drug classes: polyenes (e.g., natamycin, amphotericin B); and azoles (e.g., voriconazole, econazole) (10, 11). Natamycin prevails as the first-line treatment option, with inclusion of voriconazole or other drugs if there is no positive response to treatment (11, 12). Better outcomes with natamycin compared to voriconazole topical treatment have been demonstrated, particularly for treating *Fusarium* spp. infections (13).

This paucity of antifungal drugs to treat fungal keratitis may be compounded (now or in the future) by the increasing global incidence of antifungal resistance (14, 15). While a broad spectrum of fungi (393 species) have been cultured from fungal keratitis patients (16), 95% of cases are caused by either *Aspergillus spp.*, *Fusarium spp.*, or *Candida spp*.. Each of these genera have been categorised by the world health organisation (WHO) as critical and high priority pathogens (17). Antimicrobial-resistant *Aspergillus* spp. is further included in the 2019 U.S. Centers for Disease Control and Prevention watch list, and drug-resistant *Candida* species are listed as serious threats (18).

Antifungal susceptibility testing of fungi cultured from fungal keratitis patients is not routinely performed and/or reported, and therefore the scale of antifungal resistance is poorly understood. Moreover, how *in vitro* antifungal MIC values relate to fungal keratitis patient treatment outcomes is unknown. This hinders development of evidence-based policy and treatment guidelines.

Herein we report on the antifungal resistance profile of fungal isolates obtained from 153 fungal keratitis patients from South India between May – August 2025. The minimum inhibitory concentration (MIC) against each of the key clinically used antifungals (natamycin, amphotericin B, voriconazole, and econazole) for treatment of fungal keratitis were determined. Participant clinical symptoms were evaluated for up to one month to explore the relationship between antifungal resistance, clinical presentation and patient outcomes.

Materials and methods

This prospective observational study was performed in the Cornea Clinic and Ocular Microbiology Laboratory of Aravind Eye Hospital, Madurai, India. The study was approved by the Institutional review board of Aravind Eye Hospital, Madurai (RET202500520).

The study included 153 consecutive culture-proven fungal keratitis cases from May to August 2025. Collection of patient clinical history, and standard clinical examination were performed. Visual acuity, location, size and features of the corneal ulcer were documented. These clinical details were captured at one-week and one-month follow-up appointments following the initial (baseline) visit, unless the patient did not attend the clinic and they were deemed “lost to follow-up”.

Corneal scraping specimens were collected at the first-appointment (at the time of study recruitment) under magnification by using a kimura spatula and evaluated with 10% potassium hydroxide wet mount and Gram stain. Subsequent scrapings were plated onto 5% sheep blood agar (incubated at 37°C) and potato dextrose agar (incubated at 25°C) and allowed to grow for at least seven days prior to testing. Any positive fungal isolate was identified to the genus or species level by Lactophenol Cotton Blue (LPCB) mount based on their spore morphology.

Antifungal susceptibility of filamentous fungi was determined using the broth microdilution method according to CLSI M38-A3 guidelines (19). The following antifungal agents were tested with the final concentration: Natamycin (0.06-32 µg/mL), amphotericin B (0.03-16 µg/mL), voriconazole (0.03-16 µg/mL), and econazole (0.03-16 µg/mL). The inoculum (conidial suspension) was prepared from 7-day-old cultures grown on potato dextrose agar and adjusted to a final inoculum of 0.4–5×10□ CFU mL^{-1} in sterile saline with 0.05% Tween 20. Natamycin, amphotericin B, voriconazole, and econazole were two-fold serially diluted in RPMI 1640 medium buffered with MOPS (pH 7.0). Each well of a 96-well microtiter plate was inoculated with 100 µL of fungal suspension and 100 µL of antifungal dilution, with growth and sterility controls included. The microtiter plates were incubated at 35°C for 48 to 72 hours. The minimum inhibitory concentration (MIC) was defined as the lowest drug concentration that resulted in complete (100%) inhibition of visible growth. Quality control was performed using reference strains.

MICs were interpreted according to CLSI breakpoints, epidemiological cut-off values where available. We used the following MIC breakpoints (20): Natamycin: ≥8.0□mg/L resistant; amphotericin B: ≥2.0□mg/L resistant; voriconazole: ≥2.0□mg/L

resistant; and econazole: ≥8.0 mg/L resistant. Susceptible-increased exposure fungal isolates were treated as susceptible for further evaluation.

Statistical analysis

Data were analysed using GraphPad Prism 10.4.2 (GraphPad Software, San Diego, CA, USA). For each antifungal tested, the mean antifungal MIC per fungi genera were compared using Kruskal-Wallis test followed by Dunn's multiple comparisons test.

Spearman's correlation was used to measure the strength and direction of association between clinical measure and $\log_2$ transformed MIC. Where applicable, participants who were lost to follow-up were excluded from analysis. Significance in correlation was considered when $P<0.01$. R_s: ±0.00-0.19 = very weak correlation; ±0.2-0.39 = weak correlation; ±0.40-0.69 = moderate correlation; ±0.7-0.89 = strong correlation; and ±0.9-1.0 = very strong correlation. Significance for participant outcome against resistant/non-resistant fungal strain was determined by Fisher's exact test, comparing healed vs not-healed outcome groups. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and ****P ≤ 0.0001.

Upset plots were produced using the UpSetR package in R (version R 4.5.0) (21).

Results

Participant demographics and sample aetiology

A total of 153 fungal keratitis patients with culture-positive samples were included in this study. Participants' ages ranged from seven to 88 years-old, with 59% identified as male (Supplementary Table S1). Half of the recruited patients had already received ocular medication when first presenting at the Aravind Eye Hospital, and had symptoms for a median time of five days. Samples from 81 patients grew *Fusarium* species (52.9%), from 33 patients *Aspergillus* species (21.6%), and 25.5% were other filamentous fungi. These included *Bipolaris spp.*, *Chaetomiaceae spp.*, *Colletotrichum spp.*, *Curvularia spp.*, *Exserohilum spp.*, *Lasiodiplodia spp.*, *Mucor spp.*, *Paecilomyces spp.*, *Papulospora equi*, *Pleiocarpon algeriense*, *Podospora spp.*, and *Scedosporium spp* (Supplementary Table S2).

Antifungal minimum inhibitory concentrations (MICs) against cultured ocular clinical isolates

MICs were available for 151 fungal isolates against natamycin, amphotericin B, voriconazole and 150 against econazole. Across all isolates, the median MICs (interquartile range; IQR) were: 2.00 (1.00-8.00) µg/mL natamycin; 2.00 (0.50-8.00) µg/mL voriconazole; 2.00 (1.00-2.00) µg/mL amphotericin B; and 2.00 (0.50-8.00) µg/mL econazole. In total, 35.8% of the isolates were resistant to natamycin, 74.8% to amphotericin B, 58.3% to voriconazole and 41.7% to econazole.

Comparison of antifungal MICs for *Fusarium* and *Aspergillus* genera identified a different resistance pattern between them and the combined other genera (Figure 1, Supplementary Figure S1).

The isolates of *Fusarium* spp. showed resistance against natamycin in 38.9% of cases, against amphotericin B in 93.5% of cases, against voriconazole in 97.5% of cases, and 76.5% of the isolates were resistant to econazole.

While the *Aspergillus spp.* isolates demonstrated high levels of resistance towards natamycin (66.7% of isolates) and amphotericin B (87.9% of isolates), only 6.1% of isolates were resistant to voriconazole, and none were resistant to econazole.

Fungal keratitis ocular isolate resistance to multiple antifungal drugs

Just 27 isolates were susceptible to all four of the antifungal drugs tested, none of those isolates being *Fusarium* spp., and only one *Aspergillus flavus* isolate. The majority (66.9%) of the ocular isolates were resistant to more than one of the antifungals. Furthermore, 23 (15.2%) *Fusarium* spp. isolates were resistant to all four antifungals (Figure 2).

Spearman's rank correlation analysis identified a very strong positive correlation between voriconazole and econazole MIC, and moderate positive correlation between amphotericin B MIC and each of the azoles ($P<0.0001$) (Table 1).

Prior use of antifungals and fungal isolate sensitivity

Many of the patients (n=74, 48%) had taken some form of topical treatment for their corneal ulcer prior to enrolment into the study. 62 (84%) of these participants had dosed at least one antibiotic, 28 (32%) had dosed at least one azole and 39 (53%) had dosed one polyene (38/39 = natamycin). 23 (31%) had previously been treated with a combination of one or more azoles and a polyene. The majority of patients

with an antifungal resistant infection had no history of taking the corresponding anti-fungal: 64.8% of patients with natamycin resistant fungi had no history of natamycin use; 99.1% of patients with amphotericin B resistance had no history of using it, similarly, 89.5% and 93.2% of patients with fungal isolates resistant to voriconazole and econazole had no history of using these antifungal drugs, respectively. However, prior use of natamycin or econazole was found to increase the relative risk of resistance by 1.7-fold (95% CI: 1.1-2.5) and 2.6-fold respectively (95% CI:1.3-6.4) (Supplementary Table S3).

Antifungal MIC: Clinical presentation and progression

The study participants underwent clinical assessment at the time of enrolment (baseline), at 1 week and at 1 month. In total, 91 (59.5%) patients had a known outcome: 59 patients healed and 32 had poor outcomes (i.e. required therapeutic penetrating keratoplasty, TPK). In total, 62 (40.5%) patients were lost to follow-up and their outcome is unknown (Supplementary Figure S2).

Key clinical measures (visual acuity, epithelial defect area, stromal infiltrate depth, and ulcer severity score) are reported in Supplementary Table S4 and Supplementary Figure S3. Epithelial defects significantly improved across the cohort within one week (P<0.0001). Ulcer severity did not improve between baseline and week one, however this was significantly improved for patients remaining in the study at one month (P<0.0001).

There was no association between patient sex or admission route (free vs paying) and MIC, however there were weak, but significant trends between patient age and voriconazole (P=0.0003) and econazole MICs (P=0.0002), with higher MICs being

associated with younger patient ages. At presentation (baseline), higher natamycin MIC very weakly correlated with a worse ulcer severity score (p=0.0016) (Supplementary Table S5).

Antifungal resistance: Clinical outcome

Once entered into the study, patient treatment plans were similar across the study cohort (Supplementary Figure S4). 80.4% of patients were prescribed natamycin plus one or more azole (healed: 81.4%; poor-outcome: 87.5%; and lost to follow-up: 77.4%), with econazole the most frequently prescribed azole. Lost to follow-up patients were excluded from study outcome analysis.

Natamycin resistance (MIC≥ 8 µg/mL) significantly affected the patient outcome (P=0.0034, Table 2), with attributable risk of a poor outcome increased by 31% (95% CI: 9% to 50%). Species sub-analysis determined that this relationship was genera dependent, and was significant for the 33 cases caused by *Aspergillus* spp. (P=0.0251, Table 2), but not for keratitis caused by *Fusarium* spp..

Discussion

Antifungal resistance is of increasing concern due to the paucity of antifungal treatments available. Increasing trends have been reported worldwide, often attributed to increased use of fungicides (azoles) in agriculture and industry, and improper medical application (22). The majority of fungi in our study were resistant to two or more antifungals, including those from both polyene and azole classes. While prior use of antibiotics has been shown to increase the MIC of ocular bacterial isolates(23) the majority of patients with resistant strains in this study had no history of taking the corresponding antifungal. This perhaps indicates that the selection pressure driving increased MICs for these isolates is occurring within the environment. Azoles are frequently used in agriculture, and concerns about the contribution of these practices to driving azole resistance are well documented (22, 24). The majority of patients attending the cornea clinic in this study are agriculture workers, and/or suffered cornea injury via vegetative matter, providing a direct route of transmission for these opportunistic pathogens from environments under high selection pressure.

Notably, while azole resistant *Aspergillus* spp. is most commonly reported in the literature as a consequence of their use in agriculture, only two (6%) of the Aspergillus isolates in this study were resistant to voriconazole, and none were resistant to econazole. This is in contrast to *Fusarium* spp, where 97% of isolates were resistant to voriconazole, and 75% were resistant to econazole. It is less clear what is driving selection pressure of fungal resistance towards amphotericin B (94% of Fusarium isolates and 88% of Aspergillus isolates) and natamycin (39% Fusarium isolates and 67% Aspergillus isolates) and warrants further investigation through a

One Health approach to examine the environment-human transmission route(24, 25).

Surveillance of present and emerging antimicrobial resistance is imperative to this agenda, and for devising local, evidence-based policies around stewardship and clinical prescribing. Despite its importance, few studies have reported the antifungal resistance profile of isolates cultured from fungal keratitis patients. Where resistance is reported, differences in resistance breakpoints among studies make comparisons challenging (12, 26-28). However, a recent 585 patient study from the UK (using the same resistance break-points as used within our study) determined antifungal MICs of corneal and contact lens isolates(20). While our study found a similar proportion of fungal isolates resistant to econazole, a substantially higher proportion of our south Indian isolates showed resistance to natamycin (36% vs 8.2%), amphotericin B (74.8% vs 27.2%) and voriconazole (58.3% vs 27%). This was more pronounced when comparing data from *Fusarium* spp., and *Aspergillus* spp. isolates across each of the antimicrobials. For example, none of the UK *Fusarium* spp. isolates showed resistance to natamycin, compared to almost 40% of our isolates. Our study identified that 94% of *Fusarium* spp. isolates were resistant to amphotericin B, compared to just one-third in the UK study, and 88% of the *Aspergillus* spp. isolates in our study were resistant to amphotericin B compared to just 3% in the UK study. These differences echo geographical differences also observed for antimicrobial resistance against bacterial isolates and highlight the need for region-specific antimicrobial resistance surveillance.

A secondary objective of our study was to examine antifungal resistance/susceptibility in relation to clinical outcomes. While our sample sizes are relatively small due to patient loss to follow-up, for those remaining in the study to a

final outcome (n=91), natamycin resistance significantly increased the relative risk of a poor outcome (i.e. TPK), compared to those which were susceptible, and this was most pronounced for cases caused by *Aspergillus* spp.. However, our analysis also determined that higher natamycin MIC correlated with increased time to seek healthcare and a worse ulcer severity score at the time of presentation – both known risk factors for poor outcomes (2). Whether natamycin resistance is truly causative of worse clinical outcomes is unclear (29, 30), and warrants further investigation in adequately powered studies with standardised methodologies.

As already discussed, few fungal keratitis antifungal resistance studies have been reported, and even fewer have reported concurrent multidrug resistance profiles and/or how resistance may affect patient outcomes. This is a particular strength of our study. A limitation of ours and other studies is the lack of standardised, clinically appropriate MIC breakpoints for fungal keratitis. MICs are typically based on systemic drug concentrations, rather than topical application, where the local concentration of the drug may be higher. Furthermore, they do not consider the increased MIC required to treat fungal biofilms, which can be prevalent in fungal keratitis cases (4, 31), nor species-specific differences in breakpoints. For example, based on our study breakpoints, 13 out of 14 “poor outcome” *Aspergillus* spp. patients were treated with an “appropriate” azole based on the susceptibility profile, whereas 25% of patients with *Fusarium* infections successfully healed, despite having isolates resistant to all of their prescribed drugs, based on *in vitro* MIC values.

A systematic review on the topic is warranted to consolidate the literature and identify key areas of uncertainty and contribute to standardised reporting methodology, and disease and species-specific MIC breakpoints. Interpreting antifungal MIC and clinical consequences of resistance are imperative to the

stewardship of existing antimicrobials and the development of new therapeutic strategies.

Acknowledgements:

BM, LF and FB were supported by a UKRI Future Leaders Fellowship (United Kingdom, No. MR/V026097/1). There are no further financial disclosures or conflicts of interest.

Author Contributions (CRediT):

LF: Formal analysis, Data curation, Writing – original draft; RV: Data curation, Investigation, Writing – review and editing; FB: Formal analysis, Writing – original draft; MVD: Data curation, Investigation; RSN: Data curation, Investigation; RK: Data curation, Investigation; VP: Conceptualization, Data curation, Methodology, Supervision, Writing – review and editing; BM: Conceptualization; Funding acquisition, Data curation, Methodology, Supervision, Writing – original draft & PL: Conceptualization, Data curation, Methodology, Supervision, Writing – review and editing.

Data availability statement: Data are available on reasonable request. Supplementary information is available at Eye's website.

For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Ethics Statement: The study was approved by the Institutional Review Board of Aravind Eye Hospital, Madurai (RET202500520).

References

1. Hoffman JJ, Burton MJ, Leck A. Mycotic Keratitis-A Global Threat from the Filamentous Fungi. J Fungi (Basel). 2021;7(4):273. DOI: 10.3390/jof7040273
2. Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. The Lancet Infectious Diseases. 2021;21(3):e49-e57. DOI: 10.1016/S1473-3099(20)30448-5
3. Ong HS, Fung SSM, Macleod D, Dart JKG, Tuft SJ, Burton MJ. Altered Patterns of Fungal Keratitis at a London Ophthalmic Referral Hospital: An Eight-Year Retrospective Observational Study. Am J Ophthalmol. 2016;168:227-36. DOI: 10.1016/j.ajo.2016.05.021
4. Fingerhut L, Cheng KKW, Ali A, Mills B. Implications of Fungal Biofilms in Microbial Keratitis. Fungal Biofilms. 2025:335-94. DOI: https://doi.org/10.1007/978-3-031-93315-8_15
5. Janmohamed IK, Oguntoye O, Fu L, Robson C, Elalfy M, Maqsood S. 10-year analysis of microbiological profiles and in vitro antimicrobial susceptibility: the Kent microbial keratitis study. Eye. 2026:1-9. DOI: https://doi.org/10.1038/s41433-026-04302-w
6. Brown L, Kamwiziku G, Oladele RO, Burton MJ, Prajna NV, Leitman TM, Denning DW. The case for fungal keratitis to be accepted as a neglected tropical disease. Journal of Fungi. 2022;8(10):1047. DOI: 10.3390/jof8101047
7. Ung L, Acharya NR, Agarwal T, Alfonso EC, Bagga B, Bispo PJ, et al. Infectious corneal ulceration: a proposal for neglected tropical disease status. Bull World Health Organ. 2019;97(12):854-6. DOI: 10.2471/BLT.19.232660
8. Mills B, Radhakrishnan N, Karthikeyan Rajapandian SG, Rameshkumar G, Lalitha P, Prajna NV. The role of fungi in fungal keratitis. Exp Eye Res. 2021;202:108372. DOI: 10.1016/j.exer.2020.108372
9. Prajna NV, Srinivasan M, Lalitha P, Krishnan T, Rajaraman R, Ravindran M, et al. Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol. 2013;131(8):1088-9. DOI: 10.1001/jamaophthalmol.2013.1612
10. Hoffman JJ, Arunga S, Mohamed Ahmed AH, Hu VH, Burton MJ. Management of filamentous fungal keratitis: a pragmatic approach. Journal of Fungi. 2022;8(10):1067. DOI: 10.3390/jof8101067
11. Awad R, Ghaith AA, Awad K, Mamdouh Saad M, Elmassry AA. Fungal Keratitis: Diagnosis, Management, and Recent Advances. Clin Ophthalmol. 2024;18:85-106. DOI: 10.2147/OPTH.S447138
12. Prajna NV, Lalitha P, Krishnan T, Rajaraman R, Radnakrishnan N, Srinivasan M, et al. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials. JAMA Ophthalmology. 2022;140(2):179-84. DOI: 10.1001/jamaophthalmol.2021.5765
13. Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131(4):422-9. DOI: 10.1001/jamaophthalmol.2013.1497
14. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383-e92. DOI: 10.1016/S1473-3099(17)30316-X
15. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739-42. DOI: 10.1126/science.aap7999
16. Bartimote C, Foster J, Watson S. The spectrum of microbial keratitis: An updated review. The Open Ophthalmology Journal. 2019;13(1):100-30. DOI: 10.2174/1874364101913010100
17. WHO fungal priority pathogens list to guide research, development and public health action. . 2022. DOI: ISBN 978-92-4-006024-1
18. Antibiotic Resistance Threats in the United States. US Department of Health and Human Services, CDC. 2019. DOI: http://dx.doi.org/10.15620/cdc:82532.

19. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed. CLSI standard M38. Wayne, PA: Clinical and Laboratory Standards Institute;. 2017. DOI: ISBN 1-56238-831-2
20. Tuft S, Stone NRH, Burton MJ, Johnson EM, Borman AM. Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom. Eye (Lond). 2024;38(3):529-36. DOI: 10.1038/s41433-023-02719-1
21. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33(18):2938-40.
22. Verweij PE, Lucas JA, Arendrup MC, Bowyer P, Brinkmann AJF, Denning DW, et al. The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biol Rev. 2020;34(4):202-14. DOI: 10.1016/j.fbr.2020.10.003
23. Ray KJ, Prajna L, Srinivasan M, Geetha M, Karpagam R, Glidden D, et al. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis. JAMA ophthalmology. 2013;131(3):310-3. DOI: 10.1001/jamaophthalmol.2013.1718
24. Fisher MC, Burnett F, Chandler C, Gow NA, Gurr S, Hart A, et al. A one health roadmap towards understanding and mitigating emerging Fungal Antimicrobial Resistance: fAMR. npj Antimicrobials and Resistance. 2024;2(1):36.
25. van Rhijn N, Rhodes J. Evolution of antifungal resistance in the environment. Nature Microbiology. 2025;10(8):1804-15.
26. Soleimani M, Izadi A, Khodavaisy S, Dos Santos CO, Tehupeiory-Kooreman MC, Ghazvini RD, et al. Fungal keratitis in Iran: Risk factors, clinical features, and mycological profile. Front Cell Infect Microbiol. 2023;13:1094182. DOI: 10.3389/fcimb.2023.1094182
27. Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am J Ophthalmol. 2008;146(2):260-5. DOI: 10.1016/j.ajo.2008.04.019
28. Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, Revathi R, Anita R, Banawas S, et al. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of Fusarium and Aspergillus Isolates from Corneal Scrapings. Biomed Res Int. 2019;2019:6395840. DOI: 10.1155/2019/6395840
29. Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O'Brien KS, et al. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology. 2014;121(8):1495-500 e1. DOI: 10.1016/j.ophtha.2014.03.004
30. Lu L, Prajna NV, Lalitha P, Rajaraman R, Srinivasan M, Arnold BF, et al. Association between in vitro susceptibility and clinical outcomes in fungal keratitis. J Ophthalmic Inflamm Infect. 2024;14(1):42. DOI: 10.1186/s12348-024-00418-w
31. Zhang X, Sun X, Wang Z, Zhang Y, Hou W. Keratitis-associated fungi form biofilms with reduced antifungal drug susceptibility. Invest Ophthalmol Vis Sci. 2012;53(12):7774-8. DOI: 10.1167/iovs.12-10810

Titles and legends to figures:

Figure 1. Minimum inhibitory concentrations (MICs) of antifungals against fungal keratitis isolates. MIC [µg/mL] of the antifungals a) natamycin, b) amphotericin B, c) voriconazole and d) econazole against fungal isolates cultured from fungal keratitis patients. Cut-off values for resistance are 8 µg/mL for natamycin and econazole, and 2 µg/mL for voriconazole and amphotericin B (depicted by horizontal line). Statistical analysis was performed by Kruskal-Wallis test followed by Dunn's multiple comparisons test (**$p<0.01$, ***$p<0.001$, ****$p<0.0001$). Each data point represents one isolate.

Figure 2. Concurrent resistance of fungal keratitis isolates to antifungal drugs. Upset plots depicting the number of a) all fungal isolates; b) Fusarium spp.; and c) Aspergillus spp. isolates with resistance to common antifungal drugs. MIC cut-off values for resistance are 8 µg/mL for natamycin and econazole, and 2 µg/mL for voriconazole and amphotericin B. Black dots indicate resistance.

Table 1: Correlation between fungal isolate MICs					
MIC	**r_s**	**95% CI**	**Strength of correlation**	**P**	(n)
Natamycin vs Amphotericin B	0.30	0.14 to 0.44	weak	0.0002	151
Natamycin vs Voriconazole	0.21	0.052 to 0.37	weak	0.0082	151
Natamycin vs Econazole	0.17	0.002 to 0.32	very weak	0.0413	150
Amphotericin B vs Voriconazole	0.49	0.35 to 0.60	moderate	<0.0001	151
Amphotericin B vs Econazole	0.53	0.39 to 0.64	moderate	<0.0001	150
Voriconazole vs Econazole	0.87	0.82 to 0.90	very strong	<0.0001	150
Trends determined by Spearman's rank correlation coefficient. Positive r_s indicates positive correlation. Significance considered when P<0.01					

Table 2. Patient outcome in relation to anti-fungal resistance

	Patient Outcome				P	Relative Risk	95% CI
	Healed		Non-healed				
	N	(%)	N	(%)			
All Fungal Isolates							
Natamycin							
Susceptible	43	(76.8)	13	(23.2)	**0.0034**	**1.7**	**1.2 to 2.6**
Resistant	16	(45.7)	19	(54.3)			
Amphotericin B							
Susceptible	15	(71.4)	6	(28.6)	0.6047	1.1	0.77 to 1.5
Resistant	44	(62.9)	26	(37.1)			
Voriconazole							
Susceptible	21	(56.8)	16	(43.2)	0.1903	0.81	0.56 to 1.1
Resistant	38	(70.4)	16	(29.6)			
Econazole							
Susceptible	30	(61.2)	19	(38.8)	0.5116	0.89	0.65 to 1.2
Resistant	29	(69.1)	13	(30.9)			
***Fusarium* spp. Isolates**							
Natamycin							
Susceptible	25	(80.7)	6	(19.3)	0.3159	1.2	0.87 to 1.9
Resistant	12	(66.7)	6	(33.3)			
Amphotericin B							
Susceptible	1	(100)	0		>0.9999	1.3	0.27 to 13
Resistant	36	(75.0)	12	(25.0)			
Voriconazole							
Susceptible	1	(100)	0		>0.9999	1.3	0.27 to 13
Resistant	36	(75.0)	12	(25.0)			
Econazole							
Susceptible	8	(83.3)	2	(16.7)	>0.9999	1.1	0.64 to 1.5
Resistant	29	(76.5)	12	(23.5)			
***Aspergillus* spp. Isolates**							
Natamycin							
Susceptible	4	(80.0)	1	(20.0)	**0.0251**	**4.3**	**1.4 to 13**
Resistant	3	(18.8)	13	(81.2)			
Amphotericin B							
Susceptible	1	(33.3)	2	(66.7)	>0.9999	1.0	0.17 to 3.5
Resistant	6	(33.3)	12	(66.7)			
Voriconazole							
Susceptible	7	(33.3)	14	(66.7)	>0.9999	-	-
Resistant	0		1	(100)			

Econazole							
Susceptible	7	(33.33)	14	(66.7)	>0.9999	-	-
Resistant	0		0				
N= Number of participants with a specific outcome. Statistical analysis determined by Fisher's exact test on contingency data comparing patient outcomes (healed and non-healed) for resistant vs susceptible fungi.							


A
Natamycin MIC [µg/mL]
32
16
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
***
**
****
Fusarium spp.
Aspergillus spp.
Other fungi
B
Amphotericin B MIC [µg/mL]
****
****
C
Voriconazole MIC [µg/mL]
****
****
D
Econazole MIC [µg/mL]
****
****


A
Number of fungal isolates
32
27
23
18
14
14
6
5
3
2
1
Econazole
Amphotericin B
Voricanazole
Natamycin
Number of isolates


B
Number of Fusarium spp. isolates
32
23
11
4
2
2
2
1
Econazole
Amphotericin B
Voricanazole
Natamycin
Number of isolates


C
Number of Aspergillus spp. isolates
17
10
3
2
1
Econazole
Amphotericin B
Voricanazole
Natamycin
Number of isolates